Should You Buy Gilead Sciences Before Feb. 10?

Over the past two quarters, biotech leader Gilead Sciences (NASDAQ: GILD) has delivered results that exceeded analyst expectations. That's one of the reasons the stock is up 52% over the trailing-12-month period. The drugmaker is set to report its fourth-quarter earnings on Feb. 10 after the markets close. Several factors to watch could signal Gilead Sciences' medium-term outlook. Should investors buy the stock before then?Gilead Sciences' biggest growth driver for a while has been its HIV drug portfolio, particularly Biktarvy, one of the top prescribed HIV regimens. Sales growth hasn't been exceptional for Biktarvy or across Gilead Sciences' entire lineup, but Gilead Sciences' performance has been decent given strong competition and lower sales from other products, including its coronavirus therapy Veklury. For the third quarter, total revenue increased 3% year over year to $7.8 billion. Sales climbed 4% excluding Veklury. Biktarvy's revenue was up 6% year over year.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool